Acurx Pharmaceuticals, INC. (ACXP) — SEC Filings

Overview

Acurx Pharmaceuticals, INC. (ACXP) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 424B5 filed on Apr 16, 2026: Acurx Pharmaceuticals, Inc. filed a 424B5 prospectus supplement on April 16, 2026, related to its previously filed registration statement. This filing pertains to the potential offering of common stock, though specific dollar amounts or share quantities are not detailed in this excerpt.

Sentiment Summary

Across 38 filings, the sentiment breakdown is: 7 bearish, 30 neutral, 1 mixed. The dominant filing sentiment for Acurx Pharmaceuticals, INC. is neutral.

Filing Type Overview

Acurx Pharmaceuticals, INC. (ACXP) has filed 18 8-K, 1 424B5, 6 10-Q, 5 S-1, 1 DEFA14A, 3 DEF 14A, 2 10-K, 1 S-1/A, 1 SC 13G/A with the SEC between Feb 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (38)

• 8-K Filing — 8-K · Apr 16, 2026
• Acurx Pharmaceuticals Files Prospectus Supplement — 424B5 · Apr 16, 2026 Risk: medium
  Acurx Pharmaceuticals, Inc. filed a 424B5 prospectus supplement on April 16, 2026, related to its previously filed registration statement. This filing pertains
• Acurx Narrows Q3 Loss, But Going Concern Doubts Persist — 10-Q · Nov 12, 2025 Risk: high
  Acurx Pharmaceuticals, Inc. (ACXP) reported a net loss of $1,992,790 for the three months ended September 30, 2025, an improvement from a net loss of $2,821,597
• Acurx Files S-1 for Lincoln Park Resale, Eyes $9M More in Funding — S-1 · Oct 20, 2025 Risk: high
  Acurx Pharmaceuticals, Inc. (ACXP) filed an S-1 to register an additional 585,000 shares of common stock for resale by Lincoln Park Capital Fund, LLC, stemming
• Acurx Pharmaceuticals Files 8-K — 8-K · Sep 22, 2025 Risk: low
  Acurx Pharmaceuticals, Inc. filed an 8-K on September 22, 2025, reporting amendments to its articles of incorporation or bylaws and financial statements. The co
• Acurx Pharmaceuticals Files 8-K on Shareholder Vote — 8-K · Sep 19, 2025 Risk: low
  Acurx Pharmaceuticals, Inc. filed an 8-K on September 19, 2025, reporting on a submission of matters to a vote of security holders that occurred on September 16
• Acurx Pharmaceuticals Burns Cash, Eyes Partnerships Amidst Warrant Dilution — 10-Q · Aug 11, 2025 Risk: high
  Acurx Pharmaceuticals, Inc. (ACXP) reported no revenue for the three and six months ended June 30, 2025, consistent with its pre-commercial stage. The company i
• Acurx Pharmaceuticals Files Proxy Statement — DEFA14A · Aug 5, 2025 Risk: low
  Acurx Pharmaceuticals, Inc. filed a Definitive Proxy Statement (DEFA14A) on August 5, 2025. This filing is related to the company's proxy materials, which are u
• Acurx Seeks Shareholder Nod for Warrant Issuance, Stock Increase — DEF 14A · Aug 4, 2025 Risk: high
  Acurx Pharmaceuticals, Inc. (ACXP) is holding a special meeting on September 16, 2025, to address critical corporate governance and financing matters. The compa
• Acurx Pharmaceuticals Files 8-K with Key Updates — 8-K · Jul 31, 2025 Risk: medium
  Acurx Pharmaceuticals, Inc. filed an 8-K on July 31, 2025, reporting material modifications to security holder rights and other events. The filing also includes
• Acurx Pharmaceuticals Files 8-K on Shareholder Votes — 8-K · Jul 17, 2025 Risk: low
  Acurx Pharmaceuticals, Inc. filed an 8-K on July 17, 2025, to report on matters submitted to a vote of its security holders. The filing does not contain specifi
• Acurx Pharma Files S-1 for Public Offering, Eyes Capital Raise — S-1 · Jul 15, 2025 Risk: high
  Acurx Pharmaceuticals, Inc. (ACXP) filed an S-1 registration statement on July 15, 2025, for a proposed public offering of securities, indicating its intent to
• Acurx Pharmaceuticals Files 8-K with Material Agreements — 8-K · Jun 20, 2025 Risk: medium
  On June 17, 2025, Acurx Pharmaceuticals, Inc. entered into a Material Definitive Agreement. The company also reported on unregistered sales of equity securities
• Acurx Seeks Reverse Stock Split Approval Amid Listing Concerns — DEF 14A · May 29, 2025 Risk: high
  Acurx Pharmaceuticals, Inc. (ACXP) filed a DEF 14A on May 29, 2025, outlining proposals for its virtual Annual Meeting on July 17, 2025. Key proposals include t
• Acurx Pharmaceuticals Files S-1 Registration — S-1 · May 21, 2025 Risk: medium
  Acurx Pharmaceuticals, Inc. filed an S-1 registration statement with the SEC on May 21, 2025. The company, incorporated in Delaware, is seeking to register secu
• Acurx Pharmaceuticals Files 8-K on Financials — 8-K · May 13, 2025 Risk: low
  Acurx Pharmaceuticals, Inc. filed an 8-K on May 13, 2025, reporting on its results of operations and financial condition. The filing includes financial statemen
• Acurx Pharmaceuticals Q1 2025: Net Loss Narrows to $17.03M — 10-Q · May 12, 2025 Risk: medium
  Acurx Pharmaceuticals, Inc. filed its quarterly report for the period ending March 31, 2025. The company reported a net loss of $17.03 million for the three mon
• Acurx Pharmaceuticals Files 8-K on Agreements and Equity Sales — 8-K · May 8, 2025 Risk: medium
  Acurx Pharmaceuticals, Inc. filed an 8-K on May 8, 2025, reporting on the entry into a material definitive agreement and unregistered sales of equity securities
• Acurx Pharmaceuticals Files S-1 Registration — S-1 · Apr 4, 2025 Risk: medium
  Acurx Pharmaceuticals, Inc. filed an S-1 registration statement on April 4, 2025, to register securities under the Securities Act of 1933. The company, incorpor
• Acurx Pharmaceuticals Faces Delisting Notice — 8-K · Mar 28, 2025 Risk: high
  Acurx Pharmaceuticals, Inc. received a notice on March 25, 2025, indicating a failure to meet a continued listing rule or standard, potentially leading to a tra
• Acurx Pharmaceuticals Files 8-K on Financials — 8-K · Mar 18, 2025 Risk: low
  Acurx Pharmaceuticals, Inc. filed an 8-K on March 18, 2025, reporting on its results of operations and financial condition. The filing includes financial statem
• Acurx Pharmaceuticals Files 2024 10-K, Reports Capital Activities — 10-K · Mar 17, 2025 Risk: medium
  Acurx Pharmaceuticals, Inc. filed its 2024 10-K on March 17, 2025, reporting its financial performance for the fiscal year ending December 31, 2024. The company
• Acurx Pharmaceuticals Files 8-K: Material Agreement & Equity Sales — 8-K · Mar 10, 2025 Risk: medium
  On March 6, 2025, Acurx Pharmaceuticals, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities
• Acurx Pharmaceuticals Faces Delisting Concerns — 8-K · Feb 26, 2025 Risk: high
  Acurx Pharmaceuticals, Inc. filed an 8-K on February 26, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The f
• Acurx Pharmaceuticals Files S-1 — S-1 · Jan 31, 2025 Risk: medium
  Acurx Pharmaceuticals, Inc. filed an S-1 form on January 31, 2025, detailing its business operations and financial status. The company, incorporated in Delaware
• Acurx Pharmaceuticals Files 8-K: Material Agreement & Equity Sales — 8-K · Jan 7, 2025 Risk: medium
  Acurx Pharmaceuticals, Inc. entered into a material definitive agreement on January 6, 2025. The company also reported unregistered sales of equity securities a
• Acurx Pharmaceuticals Files 8-K for Financial Updates — 8-K · Nov 13, 2024 Risk: low
  Acurx Pharmaceuticals, Inc. filed an 8-K on November 13, 2024, to report on its results of operations and financial condition, as well as to file financial stat
• Acurx Pharmaceuticals Q3 2024 Update — 10-Q · Nov 12, 2024 Risk: medium
  Acurx Pharmaceuticals, Inc. filed its quarterly report for the period ending September 30, 2024. The company reported total assets of $16,770,378 and total liab
• Acurx Pharmaceuticals Files 8-K — 8-K · Aug 9, 2024 Risk: low
  Acurx Pharmaceuticals, Inc. filed an 8-K on August 9, 2024, reporting on its results of operations and financial condition, as well as financial statements and
• Acurx Pharmaceuticals Files Q2 2024 10-Q — 10-Q · Aug 8, 2024 Risk: medium
  Acurx Pharmaceuticals, Inc. filed its 10-Q for the period ending June 30, 2024. The filing details financial performance and operational updates for the second
• Acurx Pharmaceuticals Files 8-K on Shareholder Vote Matters — 8-K · Jun 17, 2024 Risk: low
  Acurx Pharmaceuticals, Inc. filed an 8-K on June 17, 2024, to report on matters submitted to a vote of its security holders. The filing details the company's co
• Acurx Pharmaceuticals Files 8-K on Financials — 8-K · May 15, 2024 Risk: low
  Acurx Pharmaceuticals, Inc. filed an 8-K on May 15, 2024, reporting on its results of operations and financial condition. The filing includes financial statemen
• Acurx Pharmaceuticals, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 14, 2024 Risk: low
  Acurx Pharmaceuticals, Inc. (ACXP) filed a Quarterly Report (10-Q) with the SEC on May 14, 2024. Acurx Pharmaceuticals, Inc. filed a 10-Q report for the period
• Acurx Pharmaceuticals, Inc. Announces 2024 Annual Meeting of Stockholders — DEF 14A · Apr 29, 2024 Risk: low
  Acurx Pharmaceuticals, Inc. (ACXP) filed a Proxy Statement (DEF 14A) with the SEC on April 29, 2024. Acurx Pharmaceuticals, Inc. will hold its 2024 annual meeti
• Acurx Pharmaceuticals Files Amendment to S-1 Registration Statement — S-1/A · Mar 29, 2024 Risk: low
  Acurx Pharmaceuticals, Inc. (ACXP) filed a Amended IPO Registration (S-1/A) with the SEC on March 29, 2024. Acurx Pharmaceuticals, Inc. filed an amendment (S-1/
• Acurx Pharmaceuticals Files 8-K — 8-K · Mar 18, 2024 Risk: low
  Acurx Pharmaceuticals, Inc. filed an 8-K on March 18, 2024, reporting on its results of operations and financial condition, as well as financial statements and
• Acurx Pharmaceuticals Files 2023 Annual Report on Form 10-K — 10-K · Mar 15, 2024 Risk: low
  Acurx Pharmaceuticals, Inc. (ACXP) filed a Annual Report (10-K) with the SEC on March 15, 2024. Acurx Pharmaceuticals, Inc. filed its 10-K report for the fiscal
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024

Related Companies

ACRX

Frequently Asked Questions